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Article Information  ABSTRACT 
Received: 13th May 2019  Obesity is defined as the condition in which the Body Mass Index (BMI) of an individual is 
between 25 and 29.5 that is ≥30kg/m2 and is caused by the imbalance management of energy 
intake and expenditure. Obesity is among the most prevalent diseases in the world and 
approximately over 10% of the people belong to overweight group in the world and over 5% in 
India.  Currently many drugs are used to treat or to manage obesity. But these drugs also account 
for several side effects. So there is an extensive need of promising drugs which can control 
obesity with greater efficacy and economic viability. This review focusses on the current drugs in 
the market used to treat obesity and also few of the new probable targets to discover drugs. 
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INTRODUCTION 
Obesity, the most common and complex disorders of this 
generation caused due to reasons like genetic heredity, diet and 
environmental factors [1]. Obesity can be defined as a state of 
an individual where the Body mass index (BMI) is more 
≥30kg/m2 and is caused by the imbalance management of 
energy intake and expenditure. Obesity is more common in the 
youngsters when compared to the elder people mainly due to 
the lifestyle. Obesity has a major influence on social and 
psychological status of a person which eventually causes 
depression. Physiologically it will also cause many of the 
diseases including cardiac problems [2]. In the world 
approximately 10% of the population belongs to overweight 
group. Over 40 million children under age of 5 and 340 million 
above the age of 5 are obese in the year 2016 [4, 5]. USA, 
China, India will occupy more than 50% of the obesity in the 
world. Currently, there are many drugs are used for the 
treatment of obesity but these drugs have numerous side 
effects. Therefore, there is an extensive need of such a kind of 
drugs which can control obesity with greater efficacy and 
economic viability [3].  
Major pathogenesis occurs due to either over appetite or 
dysregulation of energy utilizing functions in the body. This 
kind of situation results in accumulation of fat that in turn 
makes more adipose tissue. This alerts the secretion of cytokine 
in higher amount and thereby causes vascular complications 
due to hyperlipidemia. This may in turn cause cardiovascular 
diseases and in most cases liver, gall stone and gut related 
diseases. Therefore management of the obesity is very much 
essential to restrain these diseases [5].  It is very important to 
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maintain the fatty acids, triglycerides and cholesterol in the 
blood at very low level because higher amount of these 
molecules will start accumulating in the adipose all over the 
body called atherosclerosis and if it is not controlled may lead 
to myocardial infarction and stroke. This also results in the 
increase of oxidative stress, lipotoxicity, hypertriglyceridemia 
and other complications like diabetes. Managing and reducing 
the oxidative stress to prevent the obesity and few other 
complications [5]. 
Obesity anyhow can be managed either by reducing the 
appetite or by enhancing the calorie utilization. Hunger and 
satiety are managed by regulating the hormones which are 
responsible for hunger. However physical exercise can prevent 
the accumulation of white adipose [6].  The goal of treatment is 
to make the individual to attain and stay at healthy weight. The 
preliminary treatment target is a sudden loss of weight of 5% to 
10% of the total weight. However, loss of more weight has 
greater benefits [7]. If the individual wants to reduce weight, 
the person must change eating habits and do lot of physical 
exercise [8]. The treatment methods which are right for the 
individual directly depend on the obesity severity, health and 
the enthusiasm in willingness in losing weight. Doctors may 
recommend medication for the weight loss only if the other 
plans like diet and exercise do not work [9].  Doctors will 
consider the health history of the person and possible side 
effects before choosing any medication for the obese patient 
[10]. Few of the medications can’t be given to pregnant women 
and to the people with chronic health diseases [11]. Plethora of 
information available in the literature suggests that variety of 
drugs used treat obesity [12-26].  
Medication for obesity is so interesting and confusing that one 
medicine can’t react the same way to others and in few cases 
the effects may be slower as the time passes. Pausing or 
stopping of the medication will result in the regain of the full or 
little weight which was lost. Keeping these things in mind, a 
common, economically viable and effective drug is required to 
control obesity and with a proper diet plan which can 
substantially decrease the obesity of the individual. 
 
Physiological study of Obesity 
Development of obesity involves various pathological events at 
molecular level. Excess intake of food and less physical 
exercise leads to the condition of obesity [27]. A few number 
of the cases are due to genetic inheritance, medical problems or 
psychiatric problems [28]. Obesity occurs due to the interplay 
between genetic and also environmental factors. All the People 
who exposed urban and rural environments will become obese, 
it means that there is some genetic mechanism working at the 
individual level. Hypothalamus expresses Leptin and 
Melanocortin-4 receptors, which are involved in the regulation 
of homeostasis in the neural circuits. Inefficiency to express 
those proteins also brings obesity in the individuals [29]. 
People with multiple copies of FTO gene (Fat mass & obesity 
associated gene) are found to have 1.67 times higher risk of the 
obesity than the people who do not possess that extra copy of 
gene.  
Addition to insulin, glucagon, somatostatin, somatropin, 
cortisol, gastric inhibitory polypeptide/glucose-dependent 
insulinotropic peptide [GIP], adinopectin thyroxin, chemerin, 
perilipin-1, apelin, GLP-1 catecholamines and cholecystokinin-
pancreozymin there are other 5 molecules which are produced 
endogenously have been found to regulate the apetite, satiety, 
storage of energy and metabolism. It includes Leptin, 
Obestatin, Endocannabinoids, Ghrelin and Nesfatin-1 [29]. 
 
Current Drug based therapy for Obesity  
People with diabetes, sleep apnea, hypertension, arthritis and 
hyperlipidemia have many risk factors for the treatment of 
obesity using pharmacological therapy [30]. At present none of 
the drugs have been taken for clinical trials for more than 4 
years and also most of the drugs have serious side effects. 
Treating obese person with drugs for a short period may have 
side effects but it benefits for treating obesity. For any drug to 
consider it as antiobesity drug, it should reduce the weight at 
least by 2kg within 30 days and 5-8% in the next 180 days. 
Pharmacotherapy will be considered effective only if the 
patient loses at least 10-15% of the initial weight in 1-2 years 
period [31]. After starting treatment, decrease in the weight 
should be 10-15% of the initial weight within one year, then 
only the demonstrated therapeutic drug will be called as anti-
obesity drug. After losing weight, patients have to reduce the 
intake of energy by 8kcal/kg [32]. 
 
There are many agents used to treat obesity, they have different 
target and different mechanism of action. Appetite suppressant 
drugs, antidiabetic agents, anticonvulsant drugs, inhibitors of 
pancreatic lipase, serotonin 5-HT2c agonists, antidepressants, 
beta 3 adrenoceptor agonists, hormones and hormone 
analogues and other combinational formulae are the kind of 
drugs used in treating obesity. Clinician should select the type 
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of drug for each individual using the clinical trial data available 
and prescribe the drug along with some diet restriction and 
physical exercise. Some of the approved antiobesity drugs are 
listed in the Table 1. 
Table 1: Drugs which are approved by various authorities for treating obesity 
Drug 
Brand 
name 
Treatment 
period 
% or kg of 
weight loss 
Mechanism of action  
Drug 
Approved 
authority 
Reference 
Orlistat  Xenical 4 years Approx. 3%  TAG lipase inhibitor 
EMA, FDA, 
ANVISA 
[33,34] 
Bupropion  
Buproban, 
Wellbutrin, 
Zyban 
24 weeks Approx. 13%  
Inhibits Noradrenaline and dopamine 
reuptake 
FDA [35] 
Naltrexone/ 
bupropion  
Contrave 24 weeks 
Between 6.1 
to 9.3%  
Inhibits Opioid receptor antagonist/ 
Noradrenaline and dopamine reuptake  
EMA, FDA [36] 
Bupropion/ 
zonisamide 
Empatic 12 weeks 
Approx. 7.2 
Kg  
Inhibits Noradrenaline/ dopamine 
reuptake  
FDA [37] 
Topiramate  Topamax 24 weeks Approx. 6%  
Physiologically blocks glutamate 
receptors and carbonic anhydrase 
FDA [38] 
Phentermine  Adipex 24 weeks 
Between 7.2 
to 8.1%  
Sympathomimetic amine and appetite 
suppression  
EMA, FDA [39] 
Phentermine/ 
topiramate  
Qsymia 52 weeks Approx 9%  
Physiologically blocks glutamate 
receptors and carbonic anhydrase and 
catecholamine secretion 
FDA [40,41] 
Sibutramine  
Biomag, 
Sibus, 
Saciette 
52 weeks 4 Kg 
Block the reuptake of 5-
hydroxytryptamine and norepinephrine 
serotonin, dopamine,  
ANVISA [42] 
Rimonabant  
Acomplia, 
Redufast 
52 weeks 4-7 Kg  
Inverse agonist for the cannabinoid 
receptor CB1 
EMA [43] 
Lorcaserin  Belviq 52 weeks 
Approx. 
5.8%  
Selective agonist for  serotonin 2C 
receptor 
FDA [44,45] 
Liraglutide  
Victoza, 
Saxenda 
52 weeks 5%  Agonist for GLP-1 receptor  
EMA, FDA, 
ANVISA 
[46] 
Empagliflozin  Jardiance 3 years 1.5 to 2.0%  
Inhibits Sodium–glucose cotransporter 
2  
Phase I [47] 
Cetilistat  Cetislim 12 weeks 3.3 to 4.1%  Pancreatic lipase inhibition Japan [48,49] 
Belonarib 
Not yet 
given  
12 weeks 
Between 5-
10 Kg 
Methionine aminopeptidase 2 inhibition 
Phase II and 
III 
[50] 
 
Drugs used to treat obesity in the long term 
There are 5 different drugs or drug combination used in the 
long term to treat obesity. They are used as monotherapeutic or 
in combination therapy.  Treatment of obesity is a long term 
process and involves medication, diet and physical exercise. 
Diet and physical exercise brings about a vast difference in the 
obese individual in the long term treatment. 
Currently there are five drugs which are approved by the US 
FDA for the long term treatment of obesity. These medications 
should be taken in combination with physical exercise and 
proper diet. Orlistat, Lorcaserin, Liraglutide, Phentermine/ 
Topiramate and Naltrexone/ Bupropion are approved in the US 
and out of these, phentermine/ topiramate and lorcaserin are 
prohibited in Europe because of the safety issues [51, 52]. 
 
Orlistat 
Orlistat was first approved 
in 1998 and it is the 
longest licensed drug to 
treat obesity. In United 
Kingdom and United 
States Orlistat sold as Alli by 
GlaxoSmithKline and in most other countries as Xenical by 
Roche [53]. For the adults and adolescents of ≥12 years of age 
orlistat-120mg prescribed 3 times a day before meals [54].  
Mechanism of action: 
Orlistat is highly potent and selective inhibitor of gastric and 
pancreatic lipase and thus inhibits the digestion of triglycerides 
into fatty acids. So, absorption of fatty acids becomes limited 
and undigested triglycerides excreted through feces. 
Figure 1: Orlistat 
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Absorption of Fatty acids decreases by at least 30% after taking 
Orlistat [55]. It has to be noted that people who take low lipid 
containing diet have less significance in taking Orlistat. 
Side effects 
Some of the major side effects include gastrointestinal 
symptoms like diarrhea, abdominal pain, oily stool, fecal 
urgency and flatulence [55]. Gastrointestinal issues can be 
resolved by co-prescribing a fiber containing supplement like 
psyllium or by increasing the fiber content in the diet. 
Efficacy 
Studies have been done for 4 years to comprehend the efficacy 
of the medication [56]. Ideal impacts have been found in 
association with diet and physical exercise brought about the 
decrease of 2.9 kg that is 95% CI, 2.27-3.51 kg of the body 
weight when compared with placebo treatment. Critical loss in 
the weight of 5.8 kg versus 3.0kg; p<0.001 when compared 
with placebo treatment in the diabetic prone obese patients [57-
60]. 
 
Lorcaserin 
Lorcaserin is a specific agonist of 5-
hydroxytryptamine (5-HT) 2C 
receptor found in the hypothalamus 
region of the brain, which is known 
to control appetite. Lorcaserin was approved in 2012 for long 
term treatment of obesity, however in 2020 Lorcaserin was 
withdrawn from sale in USA because of the increased risk of 
cancer [61]. 
Mechanism of action 
Activation of 5-HT2c receptors present in the hypothalamus of 
the brain leads to the stimulation of proopiomelanocortin 
(POMC), which in turn decreases the appetite by satiety. 
Lorcaserin is a selective 5-HT2C receptor agonist, upon 
binding to the receptor, reduces the feel of appetite, mood and 
also endocrine secretion. The appropriate mechanism of 
regulation of appetite is not yet fully understood [62, 63]. 
Lorcaserin has also found to interact with the 5-HT2C related 
receptors like 5-HT2B and 5-HT2A at a ratio of 100x and 17x 
times less than that of 5-HT2C receptor [64]. 
Side effects: Nausea, dizziness, fatigue, headache, dry mouth, 
constipation, back pain, cough and hypoglycemia are the few 
of the major side effects. 
Efficacy: 
A randomized, placebo treatment controlled, double blind 
investigation with more than 3000 individuals called BLOOM 
(Behavioral Modification and Lorcaserin for Overweight and 
Obesity Management) clinical trial has been conducted to 
analyze the efficacy of lorcaserin 10mg twice day by day with 
placebo treatment. To summarize the trial, some of the patients 
who got lorcaserin in the first year asked to keep taking 
lorcaserin for the subsequent year and the rest of the patients 
were given the placebo treatment. 47.5% of patients who got 
Lorcaserin in the subsequent year lost  more than 5% of their 
initial baseline body weight in year 1 and just 20.3% of the 
placebo treatment patients shed weight by over 5% (p<0.001) 
[65, 66]. 
 
Liraglutide  
Liraglutide is 
an incretin 
mimetic 
agent which 
is an agonist 
for the 
glucogon like peptide -1 receptor. This drug was approved by 
FDA in the year 2014 for 
subcutaneous injecton of 3mg per day [67]. 
Mechanism of action  
Glucogon like peptide-1(GLP-1) binds to glucogon like peptide 
-1 receptor and enhances glucose dependent insulin secretion. 
GLP-1 has very less half-life of 1.5 to 2 minutes in the blood. 
Liraglutide is very stable in plasma and its half-life is found to 
be 13 hours [68]. The insulin produced will assist in managing 
blood glucose. GLP-1 is also known to induce postprandial 
satiety, slows down gastric emptying and decrease appetite 
[69]. 
Side effects 
Some of the major side effects subtracted with placebo were 
nausea (25.0%), diarrhea (11.6%), vomiting (12.2%), 
constipation (11.0%), and dyspepsia (6.4%) [70-72] Long term 
use of Liraglutide also leads to decrease in the level of HbA1c 
and blood pressure [73, 74]. 
Efficacy 
A 8 month clinical trial of liraglutide in 564 obese-but-non-
diabetic patients following the 5 month dose dependent 
placebo-controlled experiment of liraglutide in contrast with 
orlistat treatment (a normal weight reduction of 6.0 kg with 
liraglutide contrasted and orlistat 4.1 kg and with placebo 2.8 
kg) revealed that liraglutide at higher dose prompted 5.5 to 6.0 
kg placebo-adjusted weight reduction in one year [75].  
Figure 2 : Lorcaserin 
Figure 3 Liraglutide 
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Phentermine/topiramate  
It was the first combination drug 
approved by FDA in 2012 for the 
longer treatment of obesity. 
However it is not approved by 
EMA due to lack of long term 
studies related to cardiac related 
issues. Phentermine is a 
controlled drug substance since it comes under DEA schedule 
IV [76]. 
Mechanism of action 
This combination drug works by suppressing the appetite in an 
unknown mechanism. Phentermine is a noradrenergic agonist 
and it enhances the release of norepinephrine, serotonin and 
dopamine by its sympathetic action [77]. Topiramate is a 
glutamate antagonist, γ-aminobutyric acid agonist and carbonic 
anhydrase inhibitor and was approved for treating epilepsy and 
migranes. But the epilepsy patients who received topiramate 
have significantly lost the weight and it paved the way to study 
topiramte for clinical trials to treat obesity. The action of 
topiramate have not been understood properly, however studies 
on rats suggest that topiramte is a neurostabilizer and enhances 
thermogenesis [78-80].  
Side effects 
Dizziness, paresthesia, dysgeusia, insomnia, dry mouth, 
tingling, constipation and sleeping trouble are few of the major 
side effects of the phentermine/ topiramate. Use of this drug is 
not recommended during pregnancy [81]. 
Efficacy 
In clinical trials, individuals treated with the maximum dose of 
phentermine/topiramate along with a plan of diet and exercise 
lost 10% to 11% of their body weight contrasted with 1% to 
2% for the individuals who got placebo. Moreover, 62% to 
70% of subjects accepting the suggested dose or highest dose 
of phentermine/topiramate accomplished ≥5% weight decrease 
by week 56 (ITT-LOCF) compared with 17% to 21% of those 
getting a placebo [82]. 
 
Naltrexone/ Bupropion 
Naltrexone/bupropion is a drug combination for long term 
treatment of obesity. This combination was approved by FDA 
in 2014. Individual drugs were used in 1980s for various health 
conditions. This is not controlled substance since it poses no 
potential abuse [76]. 
 
Mechanism of action 
Synergistic effect of both Naltrexone and 
bupropion regulates the appetite and 
energy utilization. Naltrexone acts by 
inhibiting the reuptake of dopamine and 
norepinephrine and in turn it activates 
POMC in the hypothalamus. Naltrexone 
is opioid antagonist and it further 
increases the activity of Bupropion [83]. 
Side effects 
Gastro-intestinal discomforts like 
nausea, vomiting, constipation, diarrhea and other side effects 
such as headache, dizziness and dry mouth. In long term use, 
patients with CVD may pose increased level of Blood pressure 
and heart rate [84].  
Efficacy 
In a clinical trial III, patients with no T2DM medicated with 
Naltrexone/Bupropion showed effective weight decrease of up 
to 9.3% from the baseline and patients with T2DM medicated 
with Naltrexone/Bupropion showed weight decrease of up to 
5% and the data was submitted to FDA [85,86]. In 2015, 
Naltrexone/Bupropion affirmed by EMA following its 
treatment related to weight reduction in patients having BMI 
≥decrease the food admission and physical exercise in patients 
≥ 30 Kg/m2 [87] 
 
New probable targets: 
Individual can continue taking these medications as long as 
they are benefiting from treatment and not having unpleasant 
side-effects. The increase of severe obesity in the patient 
population along with the co-morbidities, demands the 
development of novel drugs for treating obesity. This 
development is due to the proper understanding of the energy 
regulation and neuronal pathways which are involved in the 
energy homeostasis. 
There are many new distinctive pathways have been studied 
which are involved in peripheral metabolic pathways. Many of 
the researchers are developing agonists for various pathways of 
peripheral metabolism like GLP-1R/Glucagon receptor twin 
agonists, triagonists for GLP-1 and GIP. One of the animal 
studies shows promising results in glycaemic management and 
weight reduction when injected with GLP-1/GIP/glucagon 
receptor triagonists [88]. Velneperit, one other drug which 
stops the binding of Neuropeptide Y to the Y5 receptor which 
reduces the hunger and thereby it manages energy balance. 
Figure 4: Phentermine/topiramate 
Figure 5: Naltrexone/ 
Bupropion 
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Velneperit showed high degree of positive response in clinical 
trials along with few side effects [50]. Cannabinoid receptor 
type 1 is one more achievable target [89]. Rimonabant is the 
antagonist and reverse agonist for CB1 receptor which reduced 
the weight rats in the animal studies [90, 91]. It is found to be 
very effective for the people who have inflated medication 
tolerance [92]. However, in 2008 due to its psychiatric side 
effects like anxiety, depression and suicide ideation 
Rimonabant was withdrawn from US market. Taranabant, one 
more CB1 receptor antagonist and it also works same as 
Rimonabant also had same psychiatric issues. So, it is believed 
that, CB1 receptor antagonists are associated with major 
psychiatric issues and the antagonist which were at the 
developing stage were halted [93]. 
Discovery of a new kind of cells called beige fat cells which 
are a kind of adipose cells, help in enhancing the hormone 
sensitivity and also involved in antiobesity effects [94]. So the 
manipulation of these beige cells would result in loss of energy 
through thermogenesis and Physical activity [95, 96]. Further 
research on those cells should be done in order to get a 
complete picture of the fact on beige cells. Some evidences 
also reveal that inflammatory mediators like fat and 
macrophages have very important role in developing obesity 
induced hormone resistance [97-99]. Demonstrations by Lee et 
al. and Lumeng et al. also revealed that obesity induces 
inflammation by changing variety of inflammatory mediators 
like WBC, Neutrophils and also Ly6chi pro-inflammatory 
monocytes [100-101]. Salicylates and pioglitazone able to 
decrease the inflammation caused in animal models [102]. 
Some anti-obesity vaccines are also under development for 
including ghrelin, somatostatin and adenovirus36. Ghrelin is an 
orexigenic molecule secreted by stomach. Anti-ghrelin vaccine 
is shown to decrease food intake and increase energy 
expenditure [103]. Somatostatin is produced by hypothalamus, 
and is known to inhibit the secretion of growth hormone and 
insulin like growth factor-1. Somatostatin vaccination increases 
the GH and IGF-1 and decreases obesity [104]. Adenovirus36 
(ad36) known to increase the risk of obesity by causing 
inflammation and adiposity [105]. 
 
CONCLUSION 
Treating obesity is still one of the complicated challenges till 
today. As this review encompasses, even though the cases of 
obesity increasing, there are drugs which can work at various 
pathways and mechanisms which can manage hunger, satiety 
and appetite. By keeping the target to progress in finding the 
better medication for obesity, existing drugs and new targets 
have to be understood properly. With the development of new 
therapeutics, anti-obesity drugs have a potential to largely 
expand and allow better as well as personalized treatment 
options. Further, studies should be carried out to prove the 
ability of the drug to reach to its target site in the body and the 
ability of the drug to adapt into environment and the lifestyle of 
the individual. Switching to healthy diet and adequate physical 
exercise as well as proper medication may be the better road to 
success. 
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